Business
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the \"Company\" or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2024 full year and fourth quarter.Full Year Fiscal 2024 HighlightsConsolidated net revenue was $81.0 million versus $107.4 million in the prior year period. The change primarily reflects the Company's wind down of its Consumer Health Segment as part of the strategic mandate to focus its business solely on its Rx Segment, in an effort to drive long-term stockholder value.ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 23% to $57.8 million versus $46.9 million in fiscal 2023. The Company expects net revenue growth across the Rx Segment in fiscal 2025.Rx Segment gross margin improved to 75% in fiscal 2024 compared to 71% in fiscal 2023.Consumer Health Segment net revenue during fiscal 2024 was $15.8 million, a decrease of 53% versus fiscal 2023, in line with the Company's strategy to discontinue the Consumer Health Segment. As previously announced, the Company completed the wind down and divestiture its Consumer Health Segment in July 2024.Net loss during fiscal 2024 was $15.8 million, or $2.86 net loss per share, compared to a net loss of $17.1 million, or $5.11 net loss per share, in fiscal 2023.Consolidated adjusted EBITDA was $9.2 million in fiscal 2024 compared to $3.5 million in fiscal 2023. The Company expects adjusted EBITDA growth in fiscal 2025.Cash and cash equivalents were $20.0 million at June 30, 2024, compared to $23.0 million at June 30, 2023.Successfully refinanced existing term loan and extended revolving credit facility on more favorable terms to the Company. In addition, the Company received $3.5 million of additional ca...